Utilization and Availability of Advanced Imaging in Patients With Acute Ischemic Stroke.


Journal

Circulation. Cardiovascular quality and outcomes
ISSN: 1941-7705
Titre abrégé: Circ Cardiovasc Qual Outcomes
Pays: United States
ID NLM: 101489148

Informations de publication

Date de publication:
04 2021
Historique:
pubmed: 25 3 2021
medline: 16 10 2021
entrez: 24 3 2021
Statut: ppublish

Résumé

Recent clinical trials have established the efficacy of endovascular stroke therapy and intravenous thrombolysis using advanced imaging, particularly computed tomography perfusion (CTP). The availability and utilization of CTP for patients and hospitals that treat acute ischemic stroke (AIS), however, is uncertain. We performed a retrospective cross-sectional analysis using 2 complementary Medicare datasets, full sample Texas and 5% national fee-for-service data from 2014 to 2017. AIS cases were identified using Among 50 797 AIS cases in the Texas Medicare fee-for-service cohort, 64% were evaluated with noncontrast head CT, 17% with CT angiography, 3% with CTP, and 33% with magnetic resonance imaging. CTP utilization was greater in patients treated with endovascular stroke therapy (17%) and intravenous thrombolysis (9%). CT angiography (4%/y) and CTP (1%/y) utilization increased over the study period. These findings were validated in the National dataset. Among hospitals in the Texas cohort, 100% were noncontrast head CT-performing, 77% CT angiography-performing, and 14% CTP-performing in 2017. Most AIS cases (69%) were evaluated at non-CTP-performing hospitals. CTP-performing hospitals were clustered in urban areas, whereas large regions of the state lacked immediate access. In state-wide and national Medicare fee-for-service cohorts, CTP utilization in patients with AIS was low, and most patients were evaluated at non-CTP-performing hospitals. These findings support the need for alternative means of screening for AIS recanalization therapies.

Sections du résumé

BACKGROUND
Recent clinical trials have established the efficacy of endovascular stroke therapy and intravenous thrombolysis using advanced imaging, particularly computed tomography perfusion (CTP). The availability and utilization of CTP for patients and hospitals that treat acute ischemic stroke (AIS), however, is uncertain.
METHODS
We performed a retrospective cross-sectional analysis using 2 complementary Medicare datasets, full sample Texas and 5% national fee-for-service data from 2014 to 2017. AIS cases were identified using
RESULTS
Among 50 797 AIS cases in the Texas Medicare fee-for-service cohort, 64% were evaluated with noncontrast head CT, 17% with CT angiography, 3% with CTP, and 33% with magnetic resonance imaging. CTP utilization was greater in patients treated with endovascular stroke therapy (17%) and intravenous thrombolysis (9%). CT angiography (4%/y) and CTP (1%/y) utilization increased over the study period. These findings were validated in the National dataset. Among hospitals in the Texas cohort, 100% were noncontrast head CT-performing, 77% CT angiography-performing, and 14% CTP-performing in 2017. Most AIS cases (69%) were evaluated at non-CTP-performing hospitals. CTP-performing hospitals were clustered in urban areas, whereas large regions of the state lacked immediate access.
CONCLUSIONS
In state-wide and national Medicare fee-for-service cohorts, CTP utilization in patients with AIS was low, and most patients were evaluated at non-CTP-performing hospitals. These findings support the need for alternative means of screening for AIS recanalization therapies.

Identifiants

pubmed: 33757311
doi: 10.1161/CIRCOUTCOMES.120.006989
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e006989

Commentaires et corrections

Type : CommentIn

Auteurs

Youngran Kim (Y)

Department of Neurology, McGovern Medical School (Y.K., S.L., R.A., V.L.-R., S.I.S., A.C., L.D.M., S.A.S.), University of Texas Health Science Center at Houston.
Division of Management, Policy and Community Health, School of Public Health (Y.K., T.M.K.), University of Texas Health Science Center at Houston.

Songmi Lee (S)

Department of Neurology, McGovern Medical School (Y.K., S.L., R.A., V.L.-R., S.I.S., A.C., L.D.M., S.A.S.), University of Texas Health Science Center at Houston.

Rania Abdelkhaleq (R)

Department of Neurology, McGovern Medical School (Y.K., S.L., R.A., V.L.-R., S.I.S., A.C., L.D.M., S.A.S.), University of Texas Health Science Center at Houston.

Victor Lopez-Rivera (V)

Department of Neurology, McGovern Medical School (Y.K., S.L., R.A., V.L.-R., S.I.S., A.C., L.D.M., S.A.S.), University of Texas Health Science Center at Houston.

Babak Navi (B)

Department of Neurology, Weill Cornell Medical College, New York, NY (B.N., H.K.).

Hooman Kamel (H)

Department of Neurology, Weill Cornell Medical College, New York, NY (B.N., H.K.).

Sean I Savitz (SI)

Department of Neurology, McGovern Medical School (Y.K., S.L., R.A., V.L.-R., S.I.S., A.C., L.D.M., S.A.S.), University of Texas Health Science Center at Houston.
Institute for Stroke and Cerebrovascular Disease (S.I.S., A.C., L.G., S.A.S.) University of Texas Health Science Center at Houston.

Alexandra L Czap (AL)

Department of Neurology, McGovern Medical School (Y.K., S.L., R.A., V.L.-R., S.I.S., A.C., L.D.M., S.A.S.), University of Texas Health Science Center at Houston.
Institute for Stroke and Cerebrovascular Disease (S.I.S., A.C., L.G., S.A.S.) University of Texas Health Science Center at Houston.

James C Grotta (JC)

Clinical Innovation and Research Institute, Memorial Hermann Hospital, Texas Medical Center, Houston (J.C.G.).

Louise D McCullough (LD)

Department of Neurology, McGovern Medical School (Y.K., S.L., R.A., V.L.-R., S.I.S., A.C., L.D.M., S.A.S.), University of Texas Health Science Center at Houston.

Trudy Millard Krause (TM)

Division of Management, Policy and Community Health, School of Public Health (Y.K., T.M.K.), University of Texas Health Science Center at Houston.

Luca Giancardo (L)

School of Biomedical Informatics (L.G.), University of Texas Health Science Center at Houston.
Institute for Stroke and Cerebrovascular Disease (S.I.S., A.C., L.G., S.A.S.) University of Texas Health Science Center at Houston.

Farhaan S Vahidy (FS)

Center for Outcomes Research, Houston Methodist Research Institute, TX (F.V.).

Sunil A Sheth (SA)

Department of Neurology, McGovern Medical School (Y.K., S.L., R.A., V.L.-R., S.I.S., A.C., L.D.M., S.A.S.), University of Texas Health Science Center at Houston.
Institute for Stroke and Cerebrovascular Disease (S.I.S., A.C., L.G., S.A.S.) University of Texas Health Science Center at Houston.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH